The Dana-Farber Cancer Institute Symposium
31 Jan 2024 | Dubai World Trade Centre | Al Ain C
The Dana-Farber Cancer Institute symposium during Arab Health 2024 is a unique opportunity to engage with leading experts and gain insights into the forefront of cancer care and research Dana-Farber Cancer Institute, distinguished for its exceptional cancer care quality and transformative research discoveries, brings decades of experience and innovation to this event.
Exploring Frontiers in Oncology: Advances and Innovation in Cancer Care and Research across Solid Tumours and Hematologic Malignancies
This symposium is particularly important for healthcare professionals, researchers, and clinicians seeking to stay at the cutting edge of oncology With Dana-Farber's legacy of groundbreaking contributions and its top-ranking status in both paediatric and adult oncology, attendees can expect to receive unparalleled knowledge on recent advances and anticipated innovations across a spectrum of disease. areas, including Lung Cancer, Breast Cancer, Genitourinary Oncology, Hematologic Malignancies, and Paediatric Oncology.
Through a series of presentations by Dana-Farber’s esteemed Harvard Medical School faculty, participants will gain insights into the latest breakthroughs that are shaping cancer diagnosis and treatment The interactive nature of the sessions, including dedicated Q&A time, encourages direct engagement with presenters, allowing attendees to seek clarification and delve deeper into the topics presented.
Additionally, the symposium fosters a platform for international collaboration The inclusion of a panel featuring Dana-Farber's experts alongside local oncologists from the GCC region underscores the importance of discussing leadership development for oncology physicians and training the next generation of oncology leaders in the Gulf This exchange of insights and best practices among professionals from diverse backgrounds enriches attendees' understanding of global trends and regional challenges in oncology
Benefits of attending:
- Unrivalled Expertise and Insights:
Dana-Farber Cancer Institute is globally recognized as a leader in oncology care and research, with a storied history of pioneering breakthroughs in cancer treatment. By attending this symposium, participants will have the opportunity to hear directly from Dana-Farber's distinguished Harvard Medical School faculty, who will present the latest advances and anticipated innovations in six distinct disease areas. This firsthand access to cutting-edge information will provide attendees with comprehensive insights into the evolving landscape of cancer prevention, diagnosis, and treatment, across solid tumour and haematological malignancies.
- Networking and Cross-Collaboration:
The symposium's inclusion of a panel featuring both Dana-Farber faculty and local oncologists from the GCC region creates a unique environment for networking and cross-collaboration. This blend of expertise ensures that attendees will not only learn from global leaders but also engage in discussions that bridge international perspectives. The opportunity to interact with experts from different regions fosters the exchange of ideas, sharing of best practices, and potential for collaborative partnerships that can enrich attendees' clinical practice, research endeavours, and patient care coordination.
- Focused and Diverse Content:
The session's well-structured outline ensures that attendees will benefit from a balanced mix of content. The brief presentations covering a range of disease areas, including Thoracic, Breast, Genitourinary, Hematologic, and Paediatric Oncology, offer a holistic overview of recent advances and future directions. The Q&A sessions after each presentation allow for direct engagement and clarification of topics. Additionally, the panel discussion involving both international and local experts offer a platform for in-depth conversations about physician leadership development.
Key topics
- Navigating the Maze: Challenges in Adjuvant Chemotherapy Decision-Making for Early-Stage Breast Cancer
- Advances in Lung Cancer Treatment in 2023
- Updates in Genitourinary Cancers: What did 2023 bring?
- Disrupting Protein-protein Interactions in a Transcriptional Complex: A promising therapeutic approach in acute myeloid leukemia
- The evolving field of gene therapy for paediatric hemoglobinopathies
Who will be attending?
- Medical Oncologists
- Surgical Oncologists
- Radiation Oncologists
- Oncology Nurses
- Oncology Pharmacists
Speakers
- Toni Choueiri, MD
• Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
• Medical Director, International Strategic Initiatives, Dana-Farber Cancer Institute
• Jerome and Nancy Kohlberg Professor of Medicine, Harvard Medical School
- Otto Metzger, MD
• Associate Medical Director, International Strategic Initiatives, Dana-Farber Cancer Institute
• Breast Oncologist, Dana-Farber Cancer Institute
• Assistant Professor of Medicine, Harvard Medical School
- Deborah Mukherji, MBBS, FRCP
• Medical Oncologist, Clemenceau Medical Center
• Faculty, American University of Beirut
- Jacob Sands, MD
• Associate Oncology Medical Director, International Patient Center, Dana-Farber Cancer Institute
• Thoracic Oncologist, Dana-Farber Cancer Institute
• Assistant Professor of Medicine, Harvard Medical School
- Leslie Lehmann, MD
• Clinical Director, Pediatric Stem Cell Transplant Program, Dana-Farber Cancer Institute
• Medical Director of International Hematology/Oncology/BMT, Boston Children’s Hospital
• Associate Professor of Pediatrics, Harvard Medical School - Dr Walid Ghazi Faraj, MD, FRCS, FACS
• Professor of Surgery, Clemenceau Medical Centre Dubai
- Richard Stone, MD
• Lunder Family Chair in Leukemia, Dana-Farber Cancer Institute
• Physician Chief of Staff, Dana-Farber Cancer Institute
• Director, Translational Research, Adult Leukemia Program, Dana-Farber Cancer Institute
• Professor of Medicine, Harvard Medical School
- Humaid Obaid bin Harmal Al Shamsi, MB, MRCP, FRCP, FACP
• Director of Burjeel Cancer Institute
• Regional Director of Burjeel Holdings Oncology UAE
• President of the Emirates Oncology Society
• Director of Innovation and Research Center, VPS Healthcare
• Adjunct Clinical Professor of Oncology at the University of Sharjah
Exclusive healthcare leadership partner
